Loading...

Donna Peehl, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentRadiology
Address1700 4th St
San Francisco CA 94158
Phone650-725-5531
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Postdoctoral FellowOncogenes
    University of California, Irvine Postdoctoral FellowTumor Suppressors
    University of Colorado, Boulder Doctor of PhilosophyMolecular, Cellular and Developmental Biology
    Stanford University, California UndergraduateBiology
    Collapse Awards and Honors
    SWIU/SBUR 2016Award for Excellence in Urologic Research

    Collapse Overview 
    Collapse Overview
    Donna Peehl, PhD, is an adjunct Professor in the Body Research Interest Group in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. She received her undergraduate degree in biology at Stanford University in California and completed her PhD in Molecular, Cellular and Developmental Biology at the University of Colorado in Boulder. During postdoctoral fellowship research at the University of California in Irvine and San Francisco, she investigated tumor suppressor genes and oncogenes in cancer. Prior to joining UCSF, Dr. Peehl became Professor Emerita at Stanford University, California, after 35 years as a basic scientist in the Department of Urology. She is widely recognized for her work in developing realistic and representative preclinical cell and tissue models of prostate and kidney cancer.

    Dr. Peehl’s current studies focus on developing novel therapeutics for prostate and kidney cancer. In collaboration with investigators at UCSF and Stanford, she is testing novel inhibitors of the tyrosine kinase AXL and of the scaffold protein, IQGAP, for their anti-cancer activity in her patient-derived models of kidney cancer. Another project uses tissue slice cultures to investigate cancer-associated glycosylation as a novel immunotherapy target. Under the auspices of a new NIH U01 grant, Dr. Peehl is collaborating with Dr. John Kurhanewicz and others at UCSF to compare metabolism of four types of kidney cancer preclinical models by hyperpolarized molecular imaging.

    Dr. Peehl has been the recipient of numerous grants from the NIH and Department of Defense (DoD) Prostate Cancer Research Program, and has received awards from the Prostate Cancer Foundation (formerly CaP CURE) to support her research. She has served as chair or scientist reviewer for many NIH and grant review panels and has reviewed or served on the editorial board for a large number of scientific journals. Her peer-reviews include over 200 articles and publications.

    Expertise:
    Urology

    Specialty:
    Prostate cancer, kidney cancer, molecular and cellular biology

    Professional Interests:
    Patient-derived xenografts, tissue slice cultures, primary cultures, spheroid cultures, preclinical drug testing, biomarkers, metabolism, cancer biology, translational science


    Collapse Research 
    Collapse Research Activities and Funding
    Metabolic imaging comparisons of patient-derived models of renal cell carcinoma
    NIH/NCI U01CA217456Sep 1, 2017 - Jul 31, 2022
    Role: Co-Principal Investigator
    A Serum Marker for Aggressive Prostate Cancer
    NIH/NCI R01CA121460Aug 28, 2006 - Jul 31, 2013
    Role: Principal Investigator
    GROWTH FACTORS IN THE PROSTATE: AN IN VITRO MODEL
    NIH/NIDDK R01DK047551Sep 30, 1993 - Aug 31, 1996
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Abrouk N, Oronsky B, Caroen S, Ning S, Knox S, Peehl D. A note on improved statistical approaches to account for pseudoprogression. Cancer Chemother Pharmacol. 2018 Mar; 81(3):621-626. PMID: 29404682.
      View in: PubMed
    2. Chen X, Nagai Y, Zhu Z, Ruan H, Peehl D, Greene MI, Zhang H. A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77. Oncotarget. 2018 Jan 09; 9(3):3631-3640. PMID: 29423071.
      View in: PubMed
    3. Spiciarich DR, Nolley R, Maund SL, Purcell SC, Herschel J, Iavarone AT, Peehl D, Bertozzi CR. Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics. Angew Chem Int Ed Engl. 2017 Jul 24; 56(31):8992-8997. PMID: 28649697.
      View in: PubMed
    4. Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl D. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clin Epigenetics. 2017; 9:4. PMID: 28149332.
      View in: PubMed
    5. Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin Investig Drugs. 2017 01; 26(1):109-119. PMID: 27935336.
      View in: PubMed
    6. Zhao H, Nolley R, Chan AMW, Rankin EB, Peehl D. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation. Cancer Biol Ther. 2017 Nov 02; 18(11):863-871. PMID: 27715452.
      View in: PubMed
    7. Türkcan S, Naczynski DJ, Nolley R, Sasportas LS, Peehl D, Pratx G. Endoscopic detection of cancer with lensless radioluminescence imaging and machine vision. Sci Rep. 2016 08 01; 6:30737. PMID: 27477912.
      View in: PubMed
    8. Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K, Peehl D, Horvath P, Mirtti T, Rannikko A, Kallioniemi O, Östling P, Af Hällström TM. Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. Eur Urol. 2017 03; 71(3):319-327. PMID: 27160946.
      View in: PubMed
    9. Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. Rockets, radiosensitizers, and RRx-001: an origin story part I. Discov Med. 2016 03; 21(115):173-80. PMID: 27115167.
      View in: PubMed
    10. Sriram R, Van Criekinge M, DeLos Santos J, Keshari KR, Wilson DM, Peehl D, Kurhanewicz J, Wang ZJ. Non-invasive differentiation of benign renal tumors from clear cell renal cell carcinomas using clinically translatable hyperpolarized 13C pyruvate magnetic resonance. Tomography. 2016 Mar; 2(1):35-42. PMID: 27227168.
      View in: PubMed
    11. Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, Marini JC, Tudawe T, Seviour EG, San Lucas FA, Alvarez H, Gupta S, Maiti SN, Cooper L, Peehl D, Ram PT, Maitra A, Nagrath D. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife. 2016 Feb 27; 5:e10250. PMID: 26920219; PMCID: PMC4841778.
    12. Valta MP, Zhao H, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimäki J, Härkönen P, Coleman I, Nelson PS, Corey E, Peehl D. Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer. Clin Exp Metastasis. 2016 Apr; 33(4):325-37. PMID: 26873136.
      View in: PubMed
    13. Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. RRx-001, A novel dinitroazetidine radiosensitizer. Invest New Drugs. 2016 06; 34(3):371-7. PMID: 26841903; PMCID: PMC4859863.
    14. Zhao H, Leppert JT, Peehl D. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data. PLoS One. 2016; 11(1):e0146505. PMID: 26814892; PMCID: PMC4729482.
    15. Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl D. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Oncotarget. 2015 Dec 22; 6(41):43172-81. PMID: 26657731; PMCID: PMC4791224.
    16. Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl D, Knox SJ, Paulmurugan R. Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001. Oncotarget. 2015 Aug 28; 6(25):21547-56. PMID: 26280276; PMCID: PMC4673285.
    17. Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl D, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA, Lao CD, Abrouk NED, Fanger GR, Infante JR. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1133-1142. PMID: 26296952.
      View in: PubMed
    18. Keshari KR, Wilson DM, Van Criekinge M, Sriram R, Koelsch BL, Wang ZJ, VanBrocklin HF, Peehl D, O'Brien T, Sampath D, Carano RA, Kurhanewicz J. Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor. Prostate. 2015 Oct; 75(14):1601-9. PMID: 26177608; PMCID: PMC4537380 [Available on 10/01/16].
    19. Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim MM, Langecker P, Fanger G. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biol. 2015 Dec; 6:1-8. PMID: 26164533; PMCID: PMC4529402.
    20. Mihelich BL, Maranville JC, Nolley R, Peehl D, Nonn L. Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One. 2015; 10(4):e0124245. PMID: 25874774; PMCID: PMC4396984.
    21. Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, Babitt JL, Lin HY, Peehl D, Torti FM, Torti SV. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 2015 Jun 01; 75(11):2254-63. PMID: 25858146; PMCID: PMC4454355.
    22. Rodrigues LU, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, Lucia MS, Wu M, Shi L, Cimic A, Sirintrapun SJ, Nolley R, Pac C, Chen H, Peehl D, Xu J, Liu W, Costello JC, Cramer SD. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 2015 Mar 15; 75(6):1021-34. PMID: 25770290; PMCID: PMC4531265.
    23. Cerchiari AE, Garbe JC, Jee NY, Todhunter ME, Broaders KE, Peehl D, Desai TA, LaBarge MA, Thomson M, Gartner ZJ. A strategy for tissue self-organization that is robust to cellular heterogeneity and plasticity. Proc Natl Acad Sci U S A. 2015 Feb 17; 112(7):2287-92. PMID: 25633040; PMCID: PMC4343104.
    24. Wang Y, Roma A, Nolley R, Abdul-Karim F, Peehl D, Eng C. Nuclear KLLN expression associates with improved relapse-free survival for prostate carcinoma. Endocr Relat Cancer. 2014 Aug; 21(4):579-86. PMID: 24972837.
      View in: PubMed
    25. Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl D. Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Lett. 2014 Sep 01; 351(2):272-80. PMID: 24998678.
      View in: PubMed
    26. Gao C, Liu Y, Zhang H, Zhang Y, Fukuda MN, Palma AS, Kozak RP, Childs RA, Nonaka M, Li Z, Siegel DL, Hanfland P, Peehl D, Chai W, Greene MI, Feizi T. Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array. J Biol Chem. 2014 Jun 06; 289(23):16462-77. PMID: 24753245; PMCID: PMC4047413.
    27. Nonaka M, Fukuda MN, Gao C, Li Z, Zhang H, Greene MI, Peehl D, Feizi T, Fukuda M. Determination of carbohydrate structure recognized by prostate-specific F77 monoclonal antibody through expression analysis of glycosyltransferase genes. J Biol Chem. 2014 Jun 06; 289(23):16478-86. PMID: 24753248; PMCID: PMC4047414.
    28. Valta MP, Zhao H, Ingels A, Thong AE, Nolley R, Saar M, Peehl D. Development of a realistic in vivo bone metastasis model of human renal cell carcinoma. Clin Exp Metastasis. 2014 Jun; 31(5):573-84. PMID: 24715498; PMCID: PMC4351963.
    29. Pu K, Shuhendler AJ, Valta MP, Cui L, Saar M, Peehl D, Rao J. Phosphorylcholine-coated semiconducting polymer nanoparticles as rapid and efficient labeling agents for in vivo cell tracking. Adv Healthc Mater. 2014 Aug; 3(8):1292-8. PMID: 24668903.
      View in: PubMed
    30. Maund SL, Nolley R, Peehl D. Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate. Lab Invest. 2014 Feb; 94(2):208-21. PMID: 24296879; PMCID: PMC3946793.
    31. Belardi B, de la Zerda A, Spiciarich DR, Maund SL, Peehl D, Bertozzi CR. Imaging the glycosylation state of cell surface glycoproteins by two-photon fluorescence lifetime imaging microscopy. Angew Chem Int Ed Engl. 2013 Dec 23; 52(52):14045-9. PMID: 24259491; PMCID: PMC3920747.
    32. Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl D. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer. 2014 May 15; 134(10):2322-9. PMID: 24243565; PMCID: PMC4365782.
    33. Tian J, Doi H, Saar M, Santos J, Li X, Peehl D, Knox SJ. Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):1179-85. PMID: 24210080.
      View in: PubMed
    34. Af Hällström TM, Zhao H, Tian J, Rantanen V, Reese SW, Nolley R, Laiho M, Peehl D. A tissue graft model of DNA damage response in the normal and malignant human prostate. J Urol. 2014 Mar; 191(3):842-9. PMID: 24035881.
      View in: PubMed
    35. Zhao H, Thong A, Nolley R, Reese SW, Santos J, Ingels A, Peehl D. Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. J Transl Med. 2013 Aug 28; 11:199. PMID: 23985008; PMCID: PMC3766103.
    36. Thong AE, Zhao H, Ingels A, Valta MP, Nolley R, Santos J, Young SR, Peehl D. Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential. Urol Oncol. 2014 Jan; 32(1):43.e23-30. PMID: 23911681; PMCID: PMC4350678.
    37. Young SR, Saar M, Santos J, Nguyen HM, Vessella RL, Peehl D. Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate. 2013 Sep; 73(12):1251-62. PMID: 23740600; PMCID: PMC3720815.
    38. Zhao H, Sun N, Young SR, Nolley R, Santos J, Wu JC, Peehl D. Induced pluripotency of human prostatic epithelial cells. PLoS One. 2013; 8(5):e64503. PMID: 23717621; PMCID: PMC3661502.
    39. Keshari KR, Sriram R, Van Criekinge M, Wilson DM, Wang ZJ, Vigneron DB, Peehl D, Kurhanewicz J. Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate. 2013 Aug; 73(11):1171-81. PMID: 23532911; PMCID: PMC3976546.
    40. Wang D, Dafik L, Nolley R, Huang W, Wolfinger RD, Wang LX, Peehl D. Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer. Drug Dev Res. 2013 Mar; 74(2):65-80. PMID: 25152555.
      View in: PubMed
    41. Wang Y, Radhakrishnan D, He X, Peehl D, Eng C. Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation. J Clin Endocrinol Metab. 2013 Mar; 98(3):E586-94. PMID: 23386643; PMCID: PMC3678149.
    42. Zhao H, Coram MA, Nolley R, Reese SW, Young SR, Peehl D. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression. J Urol. 2012 Dec; 188(6):2158-64. PMID: 23088973.
      View in: PubMed
    43. Tian J, Zhao H, Nolley R, Reese SW, Young SR, Li X, Peehl D, Knox SJ. Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Clin Cancer Res. 2012 Jun 15; 18(12):3366-76. PMID: 22535156.
      View in: PubMed
    44. Hughes AJ, Lin RK, Peehl D, Herr AE. Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):5972-7. PMID: 22474344; PMCID: PMC3341062.
    45. Wu M, Shi L, Cimic A, Romero L, Sui G, Lees CJ, Cline JM, Seals DF, Sirintrapun JS, McCoy TP, Liu W, Kim JW, Hawkins GA, Peehl D, Xu J, Cramer SD. Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res. 2012 Jun 01; 72(11):2833-43. PMID: 22467172; PMCID: PMC3654674.
    46. Ashida S, Orloff MS, Bebek G, Zhang L, Zheng P, Peehl D, Eng C. Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes. Clin Cancer Res. 2012 Mar 15; 18(6):1578-87. PMID: 22275508.
      View in: PubMed
    47. Hubbard SC, Boyce M, McVaugh CT, Peehl D, Bertozzi CR. Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells. Bioorg Med Chem Lett. 2011 Sep 01; 21(17):4945-50. PMID: 21798741; PMCID: PMC3341932.
    48. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl D, Brooks JD, Myers RM, Sherlock G. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011 Jul; 21(7):1017-27. PMID: 21521786; PMCID: PMC3129245.
    49. Brauer PM, Zheng Y, Evans MD, Dominguez-Brauer C, Peehl D, Tyner AL. The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of ß-catenin. PLoS One. 2011 Mar 30; 6(3):e14789. PMID: 21479203; PMCID: PMC3068133.
    50. Peehl D, Chen Z, Nolley R. Serum Mac-2BP does not distinguish men with high grade, large volume prostate cancer from men with benign prostatic hyperplasia. Prostate. 2011 Jan 01; 71(1):26-31. PMID: 20583127.
      View in: PubMed
    51. Peng Q, Omata S, Peehl D, Constantinou CE. Stiffness mapping prostate biopsy samples using a tactile sensor. Conf Proc IEEE Eng Med Biol Soc. 2011; 2011:8515-8. PMID: 22256325.
      View in: PubMed
    52. Tian J, Peehl D, Knox SJ. Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry. Cancer Biother Radiopharm. 2010 Aug; 25(4):439-48. PMID: 20735206.
      View in: PubMed
    53. Tian J, Peehl D, Zheng W, Knox SJ. Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. Cancer Lett. 2010 Dec 08; 298(2):231-7. PMID: 20678860.
      View in: PubMed
    54. Zhao H, Nolley R, Chen Z, Peehl D. Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol. 2010 Jul; 177(1):229-39. PMID: 20472887; PMCID: PMC2893666.
    55. Flamand V, Zhao H, Peehl D. Targeting monoamine oxidase A in advanced prostate cancer. J Cancer Res Clin Oncol. 2010 Nov; 136(11):1761-71. PMID: 20204405; PMCID: PMC2945406.
    56. Levin YS, Albers MJ, Butler TN, Spielman D, Peehl D, Kurhanewicz J. Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate. Magn Reson Med. 2009 Nov; 62(5):1091-8. PMID: 19780158; PMCID: PMC2783184.
    57. Zhao H, Flamand V, Peehl D. Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20; 2:55. PMID: 19691856; PMCID: PMC2736984.
    58. Zhao H, Peehl D. Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate. 2009 Jun 15; 69(9):991-1000. PMID: 19267366; PMCID: PMC2736596.
    59. Swami S, Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, Brooks JD, Peehl D, Feldman D. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer. 2009 May 01; 124(9):2050-9. PMID: 19127598; PMCID: PMC4777303.
    60. Norris AM, Gentry M, Peehl D, D'Agostino R, Scarpinato KD. The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):57-64. PMID: 19124481; PMCID: PMC2701238.
    61. Peehl D, Coram M, Khine H, Reese S, Nolley R, Zhao H. The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol. 2008 Nov; 180(5):2206-11. PMID: 18804811; PMCID: PMC2743604.
    62. Cramer SD, Sun J, Zheng SL, Xu J, Peehl D. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2451-7. PMID: 18768516; PMCID: PMC4114034.
    63. Kim J, Choi YL, Vallentin A, Hunrichs BS, Hellerstein MK, Peehl D, Mochly-Rosen D. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res. 2008 Aug 15; 68(16):6831-9. PMID: 18701509; PMCID: PMC2597632.
    64. Das S, Hahn Y, Walker DA, Nagata S, Willingham MC, Peehl D, Bera TK, Lee B, Pastan I. Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res. 2008 Aug 01; 68(15):6306-12. PMID: 18676855; PMCID: PMC2562772.
    65. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl D, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39. PMID: 18213636; PMCID: PMC3681409.
    66. Zhao H, Nolley R, Chen Z, Reese SW, Peehl D. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation. 2008 Sep; 76(7):820-30. PMID: 18248494; PMCID: PMC2760409.
    67. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl D, Feldman D. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res. 2007 Dec; 22 Suppl 2:V74-80. PMID: 18290727.
      View in: PubMed
    68. Feldman D, Krishnan A, Moreno J, Swami S, Peehl D, Srinivas S. Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. Nutr Rev. 2007 Aug; 65(8 Pt 2):S113-5. PMID: 17867384.
      View in: PubMed
    69. Krishnan AV, Swami S, Moreno J, Bhattacharyya RB, Peehl D, Feldman D. Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein. Nutr Rev. 2007 Aug; 65(8 Pt 2):S121-3. PMID: 17867387.
      View in: PubMed
    70. Kiviharju-af Hällström TM, Jäämaa S, Mönkkönen M, Peltonen K, Andersson LC, Medema RH, Peehl D, Laiho M. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A. 2007 Apr 24; 104(17):7211-6. PMID: 17431037; PMCID: PMC1855358.
    71. Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl D, Feldman D. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol. 2007 Mar; 103(3-5):694-702. PMID: 17229571.
      View in: PubMed
    72. Murayama Y, Omata S, Yajima T, Peng Q, Shishido K, Peehl D, Constantinou CE. High resolution regional elasticity mapping of the human prostate. Conf Proc IEEE Eng Med Biol Soc. 2007; 2007:5803-6. PMID: 18003332.
      View in: PubMed
    73. Zhao H, Ramos CF, Brooks JD, Peehl D. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol. 2007 Jan; 210(1):111-21. PMID: 17044071; PMCID: PMC2732006.
    74. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl D, Feldman D. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr. 2007 Jan; 137(1 Suppl):205S-210S. PMID: 17182827.
      View in: PubMed
    75. Nonn L, Duong D, Peehl D. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis. 2007 Jun; 28(6):1188-96. PMID: 17151092.
      View in: PubMed
    76. Bauman DR, Steckelbroeck S, Peehl D, Penning TM. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology. 2006 Dec; 147(12):5806-16. PMID: 16959841.
      View in: PubMed
    77. Moreno J, Krishnan AV, Peehl D, Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res. 2006 Jul-Aug; 26(4A):2525-30. PMID: 16886660.
      View in: PubMed
    78. Nonn L, Peng L, Feldman D, Peehl D. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 2006 Apr 15; 66(8):4516-24. PMID: 16618780.
      View in: PubMed
    79. Vaday GG, Peehl D, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2006 Feb 01; 66(2):124-34. PMID: 16161154.
      View in: PubMed
    80. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl D, Fung KM, Lin HK. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol. 2006 Mar 27; 248(1-2):182-91. PMID: 16417966.
      View in: PubMed
    81. Rose A, Xu Y, Chen Z, Fan Z, Stamey TA, McNeal JE, Caldwell M, Peehl D. Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. Cancer Lett. 2005 Sep 28; 227(2):213-22. PMID: 16112424.
      View in: PubMed
    82. Swami S, Krishnan AV, Peehl D, Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol. 2005 Sep 28; 241(1-2):49-61. PMID: 15955619.
      View in: PubMed
    83. Bauman DR, Steckelbroeck S, Williams MV, Peehl D, Penning TM. Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol. 2006 Feb; 20(2):444-58. PMID: 16179381.
      View in: PubMed
    84. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl D, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005 Sep 01; 65(17):7917-25. PMID: 16140963.
      View in: PubMed
    85. Zhao H, Lai F, Nonn L, Brooks JD, Peehl D. Molecular targets of doxazosin in human prostatic stromal cells. Prostate. 2005 Mar 01; 62(4):400-10. PMID: 15378519.
      View in: PubMed
    86. Husbeck B, Peehl D, Knox SJ. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med. 2005 Jan 01; 38(1):50-7. PMID: 15589371.
      View in: PubMed
    87. Peehl D, Feldman D. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer. J Steroid Biochem Mol Biol. 2004 Nov; 92(4):307-15. PMID: 15663994.
      View in: PubMed
    88. San Francisco IF, DeWolf WC, Peehl D, Olumi AF. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer. 2004 Nov 01; 112(2):213-8. PMID: 15352032.
      View in: PubMed
    89. Lee KL, Peehl D. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004 Nov; 172(5 Pt 1):1784-91. PMID: 15540721.
      View in: PubMed
    90. Peehl D, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, Feldman D. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol. 2004 Oct; 92(3):131-41. PMID: 15555907.
      View in: PubMed
    91. Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl D, Stewart PM, Turner BM, Campbell MJ. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene. 2004 Sep 02; 23(40):6712-25. PMID: 15300237.
      View in: PubMed
    92. Vaday GG, Hua SB, Peehl D, Pauling MH, Lin YH, Zhu L, Lawrence DM, Foda HD, Zucker S. CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin Cancer Res. 2004 Aug 15; 10(16):5630-9. PMID: 15328206.
      View in: PubMed
    93. Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D, Peehl D. Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol. 2004 Jun 30; 221(1-2):67-74. PMID: 15223133.
      View in: PubMed
    94. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl D, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate. 2004 May 15; 59(3):243-51. PMID: 15042599.
      View in: PubMed
    95. Gommersall LM, Khanim FL, Peehl D, Doherty AH, Campbell MJ. Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells. J Steroid Biochem Mol Biol. 2004 May; 89-90(1-5):251-6. PMID: 15225780.
      View in: PubMed
    96. Peehl D. Are primary cultures realistic models of prostate cancer? J Cell Biochem. 2004 Jan 01; 91(1):185-95. PMID: 14689590.
      View in: PubMed
    97. He XY, Yang YZ, Peehl D, Lauderdale A, Schulz H, Yang SY. Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 2003 Nov; 87(2-3):191-8. PMID: 14672739.
      View in: PubMed
    98. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4914-25. PMID: 14581366.
      View in: PubMed
    99. Xu Y, Iyengar S, Roberts RL, Shappell SB, Peehl D. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol. 2003 Jul; 196(1):131-43. PMID: 12767049.
      View in: PubMed
    100. Rizner TL, Lin HK, Peehl D, Steckelbroeck S, Bauman DR, Penning TM. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology. 2003 Jul; 144(7):2922-32. PMID: 12810547.
      View in: PubMed
    101. Peehl D, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr. 2003 Jul; 133(7 Suppl):2461S-2469S. PMID: 12840225.
      View in: PubMed
    102. Moore MG, Wetterau LA, Francis MJ, Peehl D, Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer. 2003 May 20; 105(1):14-9. PMID: 12672024.
      View in: PubMed
    103. Lecane PS, Kiviharju TM, Sellers RG, Peehl D. Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate. 2003 Mar 01; 54(4):258-67. PMID: 12539224.
      View in: PubMed
    104. Krishnan AV, Peehl D, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem. 2003 Feb 01; 88(2):363-71. PMID: 12520538.
      View in: PubMed
    105. Peehl D. Growth of prostatic epithelial and stromal cells in vitro. Methods Mol Med. 2003; 81:41-57. PMID: 12725113.
      View in: PubMed
    106. Krishnan AV, Peehl D, Feldman D. The role of vitamin D in prostate cancer. Recent Results Cancer Res. 2003; 164:205-21. PMID: 12899524.
      View in: PubMed
    107. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl D. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev. 2003 Jan; 12(1):23-7. PMID: 12540499.
      View in: PubMed
    108. Peehl D, Seto E, Hsu JY, Feldman D. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol. 2002 Oct; 168(4 Pt 1):1583-8. PMID: 12352462.
      View in: PubMed
    109. Shibata A, Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, Henderson S, Yemoto CE, Peehl D. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate. 2002 Sep 01; 52(4):269-78. PMID: 12210487.
      View in: PubMed
    110. Kiviharju TM, Lecane PS, Sellers RG, Peehl D. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res. 2002 Aug; 8(8):2666-74. PMID: 12171899.
      View in: PubMed
    111. Vidanes GM, Paton V, Wallen E, Peehl D, Navone N, Brooks JD. Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate. 2002 Jun 01; 51(4):225-30. PMID: 11987150.
      View in: PubMed
    112. Krishnan AV, Zhao XY, Swami S, Brive L, Peehl D, Ely KR, Feldman D. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology. 2002 May; 143(5):1889-900. PMID: 11956172.
      View in: PubMed
    113. Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl D. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol. 2002 May; 191(2):208-16. PMID: 12064464.
      View in: PubMed
    114. Guo X, Knudsen BS, Peehl D, Ruiz A, Bok D, Rando RR, Rhim JS, Nanus DM, Gudas LJ. Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res. 2002 Mar 15; 62(6):1654-61. PMID: 11912136.
      View in: PubMed
    115. Nakamura K, Yasunaga Y, Ko D, Xu LL, Moul JW, Peehl D, Srivastava S, Rhim JS. Cadmium-induced neoplastic transformation of human prostate epithelial cells. Int J Oncol. 2002 Mar; 20(3):543-7. PMID: 11836566.
      View in: PubMed
    Donna's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _